Comment on Gomez et. al. "Response to article by Wasserman et. al. (2018) 'Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico'"

Hum Vaccin Immunother. 2019;15(3):572-574. doi: 10.1080/21645515.2018.1558691. Epub 2019 Jan 18.

Abstract

In a recent Letter, Gomez et. al. provided a critique of our original analysis estimating the clinical and economic impact of switching from the 13-valent (PCV13) to the 10-valent (PCV10) pneumococcal conjugate vaccine in Mexico. This comment addresses Gomez et. al.'s comments with additional information and clarifies potential misinterpretations.

Keywords: Cost-effectiveness; Economic Evaluation; Pneumococcal Conjugate Vaccine.

Publication types

  • Comment

MeSH terms

  • Cost-Benefit Analysis
  • Humans
  • Mexico
  • Pneumococcal Infections*
  • Pneumococcal Vaccines
  • Vaccines, Conjugate

Substances

  • Pneumococcal Vaccines
  • Vaccines, Conjugate